Dixit Manisha, Liu Zhongbo, Poudel Sher Bahadur, Yildirim Gozde, Zhang Yanjiao Zhang, Mehta Shilpa, Murik Omer, Altarescu Geona, Kobayashi Yoshifumi, Shimizu Emi, Schaffler Mitchell B, Yakar Shoshana
David B. Kriser Dental Center, Department of Molecular Pathobiology New York University College of Dentistry New York New York NY USA.
Medical Genetics Institute, Shaare Zedek Medical Center Jerusalem Israel.
JBMR Plus. 2021 Mar 17;5(5):e10483. doi: 10.1002/jbm4.10483. eCollection 2021 May.
Patients with type 1 diabetes mellitus (T1DM) exhibit reduced BMD and significant increases in fracture risk. Changes in BMD are attributed to blunted osteoblast activity and inhibited bone remodeling, but these cannot fully explain the impaired bone integrity in T1DM. The goal of this study was to determine the cellular mechanisms that contribute to impaired bone morphology and composition in T1DM. Nonobese diabetic (NOD) mice were used, along with μCT, histomorphometry, histology, Raman spectroscopy, and RNAseq analyses of several skeletal sites in response to naturally occurring hyperglycemia and insulin treatment. The bone volume in the axial skeleton was found to be severely reduced in diabetic NOD mice and was not completely resolved with insulin treatment. Decreased bone volume in diabetic mice was associated with increased sclerostin expression in osteocytes and attenuation of bone formation indices without changes in bone resorption. In the face of blunted bone remodeling, decreases in the mineral:matrix ratio were found in cortical bones of diabetic mice by Raman microspectroscopy, suggesting that T1DM did not affect the bone mineralization process per se, but rather resulted in microenvironmental alterations that favored mineral loss. Bone transcriptome analysis indicated metabolic shifts in response to T1DM. Dysregulation of genes involved in fatty acid oxidation, transport, and synthesis was found in diabetic NOD mice. Specifically, pyruvate dehydrogenase kinase isoenzyme 4 and glucose transporter 1 levels were increased, whereas phosphorylated-AKT levels were significantly reduced in diabetic NOD mice. In conclusion, in addition to the blunted bone formation, osteoblasts and osteocytes undergo metabolic shifts in response to T1DM that may alter the microenvironment and contribute to mineral loss from the bone matrix. © 2021 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
1型糖尿病(T1DM)患者表现出骨密度降低和骨折风险显著增加。骨密度的变化归因于成骨细胞活性减弱和骨重塑受抑制,但这些并不能完全解释T1DM患者骨完整性受损的情况。本研究的目的是确定导致T1DM患者骨形态和成分受损的细胞机制。使用非肥胖糖尿病(NOD)小鼠,结合μCT、组织形态计量学、组织学、拉曼光谱以及对几个骨骼部位进行RNA测序分析,以研究自然发生的高血糖和胰岛素治疗的影响。发现糖尿病NOD小鼠的中轴骨骼骨体积严重减少,胰岛素治疗后也未完全恢复。糖尿病小鼠骨体积减少与骨细胞中硬化蛋白表达增加以及骨形成指标减弱有关,而骨吸收没有变化。面对骨重塑减弱的情况,通过拉曼显微光谱法发现糖尿病小鼠皮质骨的矿物质与基质比例降低,这表明T1DM本身并未影响骨矿化过程,而是导致了有利于矿物质流失的微环境改变。骨转录组分析表明,T1DM会引起代谢变化。在糖尿病NOD小鼠中发现参与脂肪酸氧化、转运和合成的基因失调。具体而言,糖尿病NOD小鼠中丙酮酸脱氢酶激酶同工酶4和葡萄糖转运蛋白1水平升高,而磷酸化AKT水平显著降低。总之,除了骨形成减弱外,成骨细胞和骨细胞会因T1DM发生代谢变化,这可能会改变微环境并导致骨基质中的矿物质流失。© 2021作者。由Wiley Periodicals LLC代表美国骨与矿物质研究学会出版。